drugset / Trial / NCT00509990

Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting

NCT00509990

Phase 4 Completed 200 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open-label, multicenter study, of long term management to evaluate effectiveness, tolerability and safety of pimecrolimus cream 1% in pediatric patients with mild to moderate atopic dermatitis in a daily practice

Timeline

Start
2005-04
Primary completion
2007-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimecrolimus Small molecule 1 %

Indications